Literature DB >> 8450180

Functional and histopathologic effects of rapamycin on mouse kidney.

J F Di Joseph1, S N Sehgal.   

Abstract

The effect of rapamycin (RAPA) on kidney function and histopathology was assessed in two strains of mice. Male C3H/HeJ mice were treated with RAPA for 4 days at doses of 25, 50, 75, and 100 mg/kg, ip and male C3H/HeJ or female Balb/cJ mice were both treated for 7 days at doses of 75, 150 and 200 mg/kg. Cyclosporine (CsA) was also administered to female Balb/cJ mice at doses of 50, 100, 150 and 200 mg/kg, ip. RAPA-treated mice had elevated BUN levels but the effect was not dose-dependent and was not present in the high dose, 7-day study conducted in the C3H/HeJ mice. Body weights were significantly depressed in both of the 7 day studies but not in the 4 day study. Histopathologic examination of the kidneys revealed the presence of intracytoplasmic vacuolization in the proximal tubules in both of the 7 day studies at the higher dose only. There were no drug-related deaths. In the CsA-treated mice, multiple deaths were recorded in both the 150 mg/kg and 200 mg/kg dose groups, probably related to neurotoxicity, and BUN levels were elevated in the 100 mg/kg dose group. In conclusion, RAPA's effects on kidney function were minimal at doses 50 times higher than its therapeutic dose established in the mouse. RAPA exhibited a better therapeutic index than CsA in the mouse.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8450180     DOI: 10.3109/08923979309066932

Source DB:  PubMed          Journal:  Immunopharmacol Immunotoxicol        ISSN: 0892-3973            Impact factor:   2.730


  3 in total

Review 1.  Roles of mTOR complexes in the kidney: implications for renal disease and transplantation.

Authors:  Daniel Fantus; Natasha M Rogers; Florian Grahammer; Tobias B Huber; Angus W Thomson
Journal:  Nat Rev Nephrol       Date:  2016-08-01       Impact factor: 28.314

Review 2.  Benefit-risk assessment of sirolimus in renal transplantation.

Authors:  Dirk R J Kuypers
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

3.  Folate-conjugated rapamycin slows progression of polycystic kidney disease.

Authors:  Jonathan M Shillingford; Christopher P Leamon; Iontcho R Vlahov; Thomas Weimbs
Journal:  J Am Soc Nephrol       Date:  2012-08-02       Impact factor: 10.121

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.